Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.
作者信息
Falini Brunangelo, Martelli Maria Paola, Pileri Stefano A, Mecucci Cristina
出版信息
Haematologica. 2010 Apr;95(4):529-34. doi: 10.3324/haematol.2009.017822.
Abstract
摘要
相似文献
1
Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.
Haematologica. 2010 Apr;95(4):529-34. doi: 10.3324/haematol.2009.017822.
2
Acute myeloid leukemia with mutated NPM1 demonstrating multilineage dysplasia and marked thrombocytosis.
Br J Haematol. 2017 Aug;178(3):350. doi: 10.1111/bjh.14741. Epub 2017 Jul 5.
3
Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia.
Blood. 2020 Sep 17;136(12):1467. doi: 10.1182/blood.2020007198.
4
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Blood. 2011 Jan 27;117(4):1109-20. doi: 10.1182/blood-2010-08-299990. Epub 2010 Oct 28.
5
Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
Hematol Oncol Stem Cell Ther. 2015 Sep;8(3):106-14. doi: 10.1016/j.hemonc.2015.06.009. Epub 2015 Jul 9.
6
Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.
Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492.
7
Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases.
Haematologica. 2014 Feb;99(2):e20-1. doi: 10.3324/haematol.2013.099754.
8
Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Cancer Treat Res. 2010;145:149-68. doi: 10.1007/978-0-387-69259-3_9.
9
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
Haematologica. 2008 Aug;93(8):1219-26. doi: 10.3324/haematol.13209. Epub 2008 Jul 4.
10
Reply to "rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases". Haematologica 2014;99(2):e20-21.
Haematologica. 2014 Feb;99(2):e22. doi: 10.3324/haematol.2013.100669.
引用本文的文献
1
A Comprehensive Genomic Analysis of Nucleophosmin (NPM1) in Acute Myeloid Leukemia.
Cancers (Basel). 2025 Aug 20;17(16):2710. doi: 10.3390/cancers17162710.
2
Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.
Blood Cancer Discov. 2024 Jan 8;5(1):8-20. doi: 10.1158/2643-3230.BCD-23-0144.
3
Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study.
Blood Cancer J. 2023 Sep 4;13(1):132. doi: 10.1038/s41408-023-00909-4.
4
Development of E-ice-COLD-PCR assay combined with HRM analysis for Nucleophosmin1 gene mutation detection in acute myelogenous leukemia.
PLoS One. 2022 Sep 14;17(9):e0274034. doi: 10.1371/journal.pone.0274034. eCollection 2022.
5
Reverse Electrochemical Sensing of FLT3-ITD Mutations in Acute Myeloid Leukemia Using Gold Sputtered ZnO-Nanorod Configured DNA Biosensors.
Biosensors (Basel). 2022 Mar 10;12(3):170. doi: 10.3390/bios12030170.
6
A Curious Novel Combination of () Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of in Acute Myeloid Leukemia (AML).
Genes (Basel). 2021 Sep 16;12(9):1426. doi: 10.3390/genes12091426.
7
-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Int J Mol Sci. 2020 Nov 26;21(23):8975. doi: 10.3390/ijms21238975.
8
Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia.
Ther Adv Hematol. 2020 Feb 3;11:2040620719899818. doi: 10.1177/2040620719899818. eCollection 2020.
9
A novel type of mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia.
Haematologica. 2018 Dec;103(12):e575-e577. doi: 10.3324/haematol.2018.190959. Epub 2018 Jun 14.
10
Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction.
Turk J Haematol. 2018 Mar 1;35(1):49-53. doi: 10.4274/tjh.2017.0095. Epub 2017 Nov 13.
本文引用的文献
1
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
J Clin Oncol. 2010 Feb 1;28(4):596-604. doi: 10.1200/JCO.2009.25.1496. Epub 2009 Dec 21.
2
Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
Am J Clin Pathol. 2010 Jan;133(1):34-40. doi: 10.1309/AJCPCI1FFE2DRXIV.
3
Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?
Haematologica. 2010 Apr;95(4):670-3. doi: 10.3324/haematol.2009.011817. Epub 2009 Dec 16.
4
Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
Blood. 2010 Jan 14;115(2):198-205. doi: 10.1182/blood-2009-04-212530. Epub 2009 Nov 9.
5
Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
Cancer. 2009 Oct 15;115(20):4737-44. doi: 10.1002/cncr.24543.
6
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
Blood. 2009 Sep 10;114(11):2220-31. doi: 10.1182/blood-2009-03-213389. Epub 2009 Jul 8.
7
Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.
Hematol Oncol. 2009 Dec;27(4):171-81. doi: 10.1002/hon.904.
8
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Leukemia. 2009 Oct;23(10):1731-43. doi: 10.1038/leu.2009.124. Epub 2009 Jun 11.
9
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
Cancer Biomark. 2009;5(1):51-8. doi: 10.3233/CBM-2009-0583.
10
Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Exp Hematol. 2009 Jan;37(1):135-42. doi: 10.1016/j.exphem.2008.09.014.
Zotero 插件